Abstract
The aim of this paper was to review the up-to-date evidence base on pharmacology and clinical properties of lurasidone.
Lurasidone is an atypical antipsychotic, approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar depression. Lurasidone exhibits both an antipsychotic and antidepressant action. Based on its pharmacodynamics profile, it is believed that the drug’s clinical action is mediated mainly through the D2, 5-HT2A and 5-HT7 receptors inhibition.
In patients with schizophrenia the recommended dose range is 40–80 mg/day. In bipolar depression broader dosage ranges (20–120 mg/day) were found to be effective. In terms of side effects, higher rates of akathisia, parkinsonism and hyperprolactinemia were observed in individuals receiving lurasidone (as compared to patients treated with other atypical antipsychotics). On the other hand, treatment with lurasidone yields relatively lower risk for developing sedation or overweight/obesity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
American Psychiatric Association. Desk reference to the diagnostic criteria from DSM-5. Arlington, VA: American Psychiatric Association; 2013.
Liperoti R, Bernabei R, Onder G. Managing antipsychotic medications in schizophrenia: comprehensive assessment and personalized care to improve clinical outcomes and reduce costs. J Clin Psychiatry 2015;76(9):e1159–60.
Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 20l0. Lancet 2012;380(9859):2129–43.
Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013;382(9904):1575–86.
Stahl SM, Morrissette DA, Citrome L, Saklad SR, Cummings MA, Meyer JM, et al. “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectr 2013;18(3):150–62.
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15(1):1–44.
De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 2012;26(9):733–59.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):951–62.
Awad AG, Voruganti LN. The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia. CNS Drugs 2013;27(8):625–36.
Patel MX, Collins S, Hellier J, Bhatia G, Murray RM. The quality of reporting of phase II and III trials for new antipsychotics: a systematic review. Psychol Med 2015;45(3):467–79.
Jarema M, Wichniak A, Dudek D, Samochowiec J, Bienkowski P, Rybakowski J. Guidelines for the use of second-generation long-acting antipsychotics. Psychiatr Pol 2015;49(2):225–41.
Downing AM, Kinon BJ, Millen BA, Zhang L, Liu L, Morozova MA, et al. A doubleblind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry 2014;14:351.
Zhang W, Mitchell MI, Knadler MP, Long A, Witcher J, Walling D, et al. Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia. Int J Clin Pharmacol Ther 2015;53(6):462–70.
Stauffer VL, Millen BA, Andersen S, Kinon BJ, Lagrandeur L, Lindenmayer JP, et al. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res 2013;150(2–3):434–41.
Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry 2014;71(6):637–46.
Bugarski-Kirola D, Wang A, Abi-Saab D, Blattler T. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia — results from the CandleLyte study. Eur Neuropsychopharmacol 2014;24(7):1024–36.
Guyatt G, Haynes B, Jaeschke R, Meade MO, Wilson M, Montori V, et al. The philosophy of evidence-based medicine. In: Guyatt G, Rennie D, Meade MO, Cook DJ, editors. Users’ guides to the medical literature: a manual for evidence-based clinical practice. McGraw-Hill; 2008. p. 9–16.
Jaeschke R, Siwek M, Brozek J, Brudkiewicz P. Randomized controlled trials in psychiatry. Psychiatr Pol 2012;46(1):109–21.
Murad MH, Montori VM, Ioannidis JP, Jaeschke R, Devereaux PJ, Prasad K, et al. How to read a systematic review and meta-analysis and apply the results to patient care: users’ guides to the medical literature. JAMA 2014;312(2):171–9.
Lochmann van Bennekom MW, Gijsman HJ, Zitman FG. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J Psychopharmacol 2013;27(4):327–36.
Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011;11(1):59–67.
Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010;334(1):171–81.
FDA. LATUDA® (lurasidone HCl) Tablets. FDA; 2010.
Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther 2012;29(10):815–25.
Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009;18(11):1715–26.
Terry Jr. AV, Buccafusco JJ, Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res 2008;195(1):30–8.
Bienkowski P, Dudek D, Samochowiec J. Towards better non-selectivity: the role of 5-HT7 receptors in therapeutic efficacy of a second-generation antipsychotic — lurasidone. Psychiatr Pol 2015;49(2):243–53.
Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses 2011;4(4):251–7.
Caccia S, Pasina L, Nobili A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatr Dis Treat 2012;8:155–68.
Preskorn S, Ereshefsky L, Chiu YY, Poola N, Loebel A. Effect of food on the pharmacokinetics oflurasidone: results oftwo randomized, open-label, crossover studies. Hum Psychopharmacol 2013;28(5):495–505.
Samalin L, Garnier M, Llorca PM. Clinical potential of Iurasidone in the management of schizophrenia. Ther Clin Risk Manag 2011;7:239–50.
Franklin R, Zorowitz S, Corse AK, Widge AS, Deckersbach T. Lurasidone for the treatment of bipolar depression: an evidence-based review. Neuropsychiatr Dis Treat 2015;11:2143–52.
Madhusoodanan S, Velama U, Parmar J, Goia D, Brenner R. A current review of cytochrome P450 interactions of psychotropic drugs. Ann Clin Psychiatry 2014;26(2):120–38.
Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact 2014;29(3):191–202.
U.S. National Library of Medicine Toxicology Data Network.
Levine M, Ruha AM. Overdose ofatypical antipsychotics: clinical presentation, mechanisms of toxicity and management. CNS Drugs 2012;26(7):601–11.
Meltzer HY, Rajagopal L, Huang M, Oyamada Y, Kwon S, Horiguchi M. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 2013;16:2181–94.
Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007;572(2–3):160–70.
Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, Toma S, Ito A. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 2008;186(2):197–207.
Murai T, Nakako T, Ikejiri M, Ishiyama T, Taiji M, Ikeda K. Effects of lurasidone on executive function in common marmosets. BehavBrain Res 2013;246:125–31.
Horiguchi M, Hannaway KE, Adelekun AE, Jayathilake K, Meltzer HY. Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. Neuropsychopharmacology 2012;37(10):2175–83.
Yuen EY, Li X, Wei J, Horiguchi M, Meltzer HY, Yan Z. The novel antipsychotic drug lurasidone enhances N-methyl-d-aspartate receptor-mediated synaptic responses. Mol Pharmacol 2012;81(2):113–9.
Horisawa T, Ishibashi T, Nishikawa H, Enomoto T, Toma S, Ishiyama T, et al. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav Brain Res 2011;220:83–90.
Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 2011;338(2):605–14.
Miyauchi M, Neugebauer NM, Oyamada Y, Meltzer HY. Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition. Behav Brain Res 2016;301:204–12.
Luoni A, Macchi F, Papp M, Molteni R, Riva MA. Lurasidone exerts antidepressant properties in the chronic mild stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex. Int J Neuropsychopharmacol 2015;18(4):pyu061.
Calabrese F, Savino E, Papp M, Molteni R, Riva MA. Chronic mild stress-induced alterations of clock gene expression in rat prefrontal cortex: modulatory effects of prolonged lurasidone treatment. Pharmacol Res 2015;104:140–50.
Cates LN, Roberts AJ, Huitron-Resendiz S, Hedlund PB. Effects of lurasidone in behavioral models of depression role of the 5-HT(7) receptor subtype. Neuropharmacology 2013;70:211–7.
Luoni A, Hulsken S, Cazzaniga G, Racagni G, Homberg JR, Riva MA. Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats. Int J Neuropsychopharmacol 2013;16(16):1319–30.
Stan TL, Sousa VC, Zhang X, Ono M, Svenningsson P. Lurasidone and fluoxetine reduce novelty-induced hypophagia and NMDA receptor subunit and PSD-95 expression in mouse brain. Eur Neuropsychopharmacol 2015;25(10):1714–22.
Fumagalli F, Calabrese F, Luoni A, Bolis F, Racagni G, Riva MA. Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int J Neuropsychopharmacol 2012;15(2):235–46.
Luoni A, Berry A, Calabrese F, Capoccia S, Bellisario V, Gass P, et al. alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence. Eur Neuropsychopharmacol 2014;24(6):986–95.
Calabrese F, Luoni A, Guidotti G, Racagni G, Fumagalli F, Riva MA. Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid. Psychopharmacology 2013;226(1):101–12.
McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry 2013;74(2):170–9.
Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res 2013;145(1–3):101–9.
Loebel A, Cucchiaro J, Silva R, Mao Y, Xu J, Pikalov A, et al. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies. Eur Psychiatry 2015;30(1):26–31.
Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr 2015;20(2):140–7.
Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 2014;40(2):314–26.
Correll C, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A. Long-term safety and effectiveness of lurasidone in schizophrenia: results of a 22 month, open-label extension study. Eur Psychiatry 2014;29:1.
Styczen K, Datka W, Jaeschke R, Drozdowicz K, Siwek M, Dudek D. The place of quetiapine extended release in the treatment of mental disorders. Psychiatr Pol 2015;49(1):67–80.
Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res 2013;147(1): 95–102.
Stahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry 2013;74(5):507–15.
Citrome L, Weiden PJ, McEvoy JP, Correll CU, Cucchiaro J, Hsu J, et al. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr 2014;19(4):330–9.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
Findlay LJ, El-Mallakh P, El-Mallakh RS. Management of bipolar I depression: clinical utility of lurasidone. Ther Clin Risk Manag 2015;11:75–81.
Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014;171(2):160–8.
Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 2014;155:20–7.
Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments metaanalysis. Acta Psychiatr Scand 2014;130(6):452–69.
Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014;171(2):169–77.
Popovic D, Benabarre A, Crespo JM, Goikolea JM, Gonzalez-Pinto A, Gutierrez-Rojas L, et al. Risk factors for suicide in schizophrenia: systematic review and clinical recommendations. Acta Psychiatr Scand 2014;130(6):418–26.
Loebel AD, Siu CO, Cucchiaro JB, Pikalov AA, Harvey PD. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. CNS Spectr 2014;19(2):197–205.
Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015;14(2):119–36.
Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360(3):225–35.
Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163(2):185–94.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Jaeschke, R.R., Sowa-Kućma, M., Pańczyszyn-Trzewik, P. et al. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. Pharmacol. Rep 68, 748–755 (2016). https://doi.org/10.1016/j.pharep.2016.04.002
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2016.04.002